Lenvima® (lenvatinib) Phase III Data in Advanced Thyroid Cancer: Live Virtual Press Event From the 15th International Thyroid Congress (ITC) 2015, Florida

- HATFIELD, England, October 15, 2015 /PRNewswire/ -- - INVITATION FOR EUROPEAN AND ASIAN  JOURNALISTS ONLY -  There is a major need for improved treatment options for radioiodine refractory differentiated thyroid cancer, an aggressive, difficult-to-treat cancer with poor prognosis and 10-year survival rates of only 15%. This virtual press event will give you the opportunity to hear about the key role of lenvatinib in thyroid cancer from two experts in the field and give you exclusive access to them for direct questions and one-to-one interviews. Professor Martin Schlumberger, University Paris Sud, France, will provide an overview of the key Lenvatinib Phase III data at ITC and focus on the effect of lenvatinib across different metastatic sites. Dr Rosella Elisei, Department of Endocrinology and Metabolism, Section of Endocrinology, University of Pisa, Italy, will provide an overview of the SELECT trial including key results and trial design. The Official ASCO Press Conference will take place on Saturday, May 31, 8:00-9:00 (CST) The press conference will be webcast. Please visit the website below for further details: http://www.asco.org/press-center/pr-professionals Eisai will be presenting seven abstracts at this year's ITC meeting which can be found below: Product Abstract Name Session Presentation Short Oral Communications Session Date: Monday, October Outcomes by site of 19, 2015 from 16:30 PM metastasis for patients with - 17:30 PM radioiodine-refractory Poster: differentiated thyroid Monday, October 19 from cancer treated with 9:20 AM - 9:45 AM and lenvatinib versus placebo: 3:05 PM- 4:00 PM results from a phase 3, Habra MA, Song J, Tuesday, October 20 randomized trial Rietschel P from 9:20 AM - 9:45 AM Monday, October 19 from 9:20 AM - 9:45 AM and 3:05 PM- 4:00 PM A Study of the Quality of Hudgens S, Pelletier Tuesday, October 20 Survival In Radioiodine C, Forsythe A, Taylor from 9:20 AM - 9:45 AM Refractory Thyroid Cancer M . Incidence and Timing of Haddad R, Schlumberger Common Adverse Events in M, Wirth L, Sherman E, Wednesday, October 21 Lenvatinib-treated Patients Shah M, Robinson B, from 9:20 AM - 9:45 AM With Radioiodine-refractory Dutcus C, Teng A, and 3:05 PM- 4:00 PM Thyroid Cancer From the Gianoukakis A, Sherman Thursday, October 22 SELECT Trial S from 9:20 AM - 10:20 AM Lenvatinib and the effect of age on overall survival for Wednesday, October 21 patients with from 9:20 AM - 9:45 AM radioiodine-refractory and 3:05 PM - 4:00 PM differentiated thyroid Brose M, Teng A, Thursday, October 22 cancer Rietschel P, Habra MA from 9:20 AM - 10:20 AM Efficacy and Safety of Lenvatinib by Body Mass Tahara M, Wirth L, Wednesday, October 21 Index in Patients With Brose M, Newbold K, from 9:20 AM - 9:45 AM 131I-refractory Schlumberger M, Ductus and 3:05 PM- 4:00 PM Differentiated Thyroid C, Robinson B, Thursday, October 22 Cancer Gianoukakis AG from 9:20 AM - 10:20 AM Number Needed to Treat (NNT) Analysis of Therapies In Wednesday, October 21 Radioiodine-Refractory from 9:20 AM - 9:45 AM Differentiated Thyroid and 3:05 PM - 4:00 PM Cancer (RAI-R DTC) Using Tremblay G, Li X, Thursday, October 22 Indirect Comparison Abouzaid S from 9:20 AM - 10:20 AM Characteristics of Patients Wednesday, October 21 on Lenvatinib With from 9:20 AM - 9:45 AM Treatment-emergent and 3:05 PM- 4:00 PM Hypertension in the SELECT Abouzaid S, Li X, Thursday, October 22 Trial Rietschel P from 9:20 AM - 10:20 AM The Official ASCO Press Conference will take place on Saturday, May 31, 8:00-9:00 (CST) The press conference will be webcast. Please visit the website below for further details: http://www.asco.org/press-center/pr-professionals This is not an official event at ITC 2015. This event is not sponsored or endorsed by ITC or the American Thyroid Association. Date of preparation: October 2015 Job code: Oncology-UK0063